ENVA · Enova International, Inc. · Stock research

Current Thesis

The binary that framed the June–July coverage has resolved. On 2026-07-23 Enova reported Q2 2026 total revenue of $929M (+22% YoY), net revenue of $568M at a 61% net revenue margin (58% in Q2 2025, above the 55–60% the company had guided), diluted EPS of $4.00 (+40% YoY) and adjusted EPS of $4.31 (+33%), and lifted the full-year frame to revenue growth of 20–25% and adjusted EPS growth of 30–35%. The fundamentals improved; what also changed is that the sell-side gap has largely closed — the post-print target band of roughly $257–$283 now brackets spot rather than sitting 30–40% above it. The narrative leg on offer today is continued 20%+ origination growth with charge-offs holding near 7.3%, priced much closer to fair than it was six weeks ago.

Bullish and bearish views on Enova International, Inc.

The model's bull view on Enova International, Inc. (ENVA), in brief: Q2 2026 (reported 2026-07-23): total revenue $929M, +22% YoY; net revenue $568M; net revenue margin 61% vs 58% in Q2 2025 — through the top of the company's own 55–60% guide. The bear view: The company itself steps the margin back down: Q3 2026 is guided to a 55–60% net revenue margin against the 61% just printed. Both cases follow in full.

Bull Case

• Q2 2026 (reported 2026-07-23): total revenue $929M, +22% YoY; net revenue $568M; net revenue margin 61% vs 58% in Q2 2025 — through the top of the company's own 55–60% guide.
• Adjusted EPS $4.31 (+33% YoY); GAAP diluted EPS $4.00 (+40%); adjusted EBITDA $256M (+26%). Adjusted EPS came in above the ~$3.96 consensus cited in post-print coverage.
• Originations $2.3B, +27% YoY — the eleventh consecutive quarter of at least 20% origination growth, with consumer +23% and small business +29% (2026-07-23 call).
• Combined loans and finance receivables $5.5B at quarter-end, +28% YoY. Small business is 69% of receivables with revenue +35% YoY; consumer is 31% with revenue +11%.
• Consolidated net charge-off ratio 7.3%, from 8.1% a year earlier and 7.6% in Q1 2026. Consumer NCO 12.8% (–170bps YoY); small business NCO 4.8%, described as stable.
• Cost of funds 8.1% vs 8.8% a year earlier (2026-07-23 call) — the funding line is improving while the book grows.
• Guidance raised on the print: FY2026 revenue +20–25% and adjusted EPS +30–35%; Q3 2026 framed at revenue ~+25% YoY and adjusted EPS ~+30% YoY.
• Grasshopper Bank ($369M, announced 2025-12-11, part cash / part newly issued shares): management said on 2026-07-23 that regulators are in "constructive dialogue" and guided to more than 25% EPS accretion once synergies are fully realised within two years of closing.
• $19M of stock repurchased in Q2 2026; liquidity (cash, securities and available capacity) of $929M.

Bear Case

• The company itself steps the margin back down: Q3 2026 is guided to a 55–60% net revenue margin against the 61% just printed. The Q2 margin beat is not carried forward in the guide.
• Management flagged on the 2026-07-23 call that "some consumer metrics may move back toward more typical levels." Consumer is only 31% of receivables but runs a 12.8% charge-off ratio.
• The revision gap has compressed. TD Cowen's post-print $257 is ~1.7% above the 2026-08-07 close of $252.64; the post-print street-high, Seaport Research at $283 from $210 (reported late July 2026), is ~12% above. In late June the $280 street-high stood roughly 38% above a ~$202 tape.
• Grasshopper is unfinished: the application was submitted 2026-01-16 and requires OCC and Federal Reserve approval plus Grasshopper stockholder approval. American Banker reported a coalition of 20 state attorneys general urging federal regulators to reject bank purchases by Enova and OppFi. Denial or slippage removes both the funding-cost and the accretion legs.
• The model is levered to charge-offs staying near current levels while the book compounds at 28% YoY. Near-prime consumer and small-business credit is high-beta to the labour market, and a high-APR lender carries a standing federal and state regulatory tail.
• Nothing company-scheduled resolves inside the next 30 days; the next dated proof point is the Q3 print (~2026-10-22, est.).

Setup & Price Structure

• Last completed daily close $252.64 (2026-08-07); 52-week high $263.02, so price sits 3.9% below it. RSI(14) 63.2 — advanced but short of an overbought extreme. Three-month return +44.4%.
• The acceleration phase is dateable and is now behind the tape: four target raises in thirteen days (Citizens $270 on 2026-06-26, BTIG $270 on 2026-06-30, TD Cowen $250 on 2026-07-07, Jefferies $280 on 2026-07-08) with spot near $202, then the 2026-07-23 beat-and-raise. Post-print revisions were increments — TD Cowen $250 → $257 — rather than the step-changes of June.
• Life-cycle: MATURING. Well known within the specialty-finance cohort, still working on the tape, with moderating incremental flow. The date stamp is 2026-07-23: the event the June revision wave was underwriting has happened and cleared, and price has absorbed most of the published target range.
• Crowding and positioning observables: targets clustering just above spot; a retrospective-performance article on 2026-08-07 (Benzinga's "$100 invested five years ago" format), a genre that follows a run; the company buying $19M of its own stock in Q2 while the Grasshopper consideration will issue new shares at close; no insider transactions in the recent filings feed for this window.
• Structure: the post-print advance runs from the pre-print low-$230s area to the $263.02 high, and price is consolidating under that high rather than making a new one. A weekly close below $225 would give the whole move back and return price into the June–July range.

Catalyst Calendar (next 30 days)

• No company-scheduled event between 2026-08-08 and 2026-09-07. That is itself the setup condition — the narrative has to hold on flow alone.
• ~2026-09-04 (BLS schedule): August employment report. The labour market is the upstream input to near-prime charge-offs; a sharp deterioration is the fastest route to a de-rating of the 7.3% NCO assumption.
• ~2026-10-22 (est., outside the 30-day window): Q3 2026 earnings — first test of the raised FY guide, and of the 55–60% net revenue margin the company guided for the quarter.

Elapsed catalysts

• Open-ended, 2H 2026 (application filed 2026-01-16): OCC / Federal Reserve decision on the $369M Grasshopper Bank acquisition. No published statutory decision date; approval or denial can land in any week and resets the funding-cost path. (passed 205d ago)

What Would Change Our Mind

A Q3 consolidated net charge-off ratio printing above 7.6% — worse than Q1 2026, reversing the improvement sequence — or a net revenue margin below the guided 55% floor, breaks the credit-normalisation leg regardless of what originations do. On price, a weekly close below $225 erases the post-Q2 advance and puts the name back inside the June–July range; that is the gradeable line. The third condition is Grasshopper: management dropping the "later this year" language, an extended review, or an OCC/Fed denial removes both the cheaper-funding and the >25% accretion arguments that the post-print targets embed. Conversely, an approval announcement with a dated closing would restore an event the calendar currently lacks.

Correlation Notes

• Specialty-consumer-credit cohort: OPFI, SOFI, LC, WRLD. The cohort trades together on credit-normalisation data, so a charge-off surprise at any of them is a read-through, not an idiosyncratic event.
• OppFi is the closest regulatory comparable — the same state-AG letter targeted both firms' bank acquisitions, so an OCC or Federal Reserve action on either deal informs the other.
• Funding-side sensitivity runs through the ABS market and front-end rates; the reported 8.1% cost of funds (Q2 2026, down from 8.8% YoY) is the line where a spread widening would show up first.
• Small-business exposure (69% of receivables) ties the book to SMB failure rates and to the labour and small-business survey data, a different cycle input from the near-prime consumer half.